Agilon Health (NYSE:AGL) Given New $1.50 Price Target at Wells Fargo & Company

Agilon Health (NYSE:AGL) had its price target lifted by equities research analysts at Wells Fargo & Company from $1.00 to $1.50 in a research note issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 157.29% from the company’s current price.

A number of other research analysts also recently commented on AGL. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Finally, Barclays cut their price target on shares of Agilon Health from $1.00 to $0.50 and set an “underweight” rating on the stock in a research note on Friday. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Agilon Health currently has an average rating of “Hold” and an average target price of $2.60.

Agilon Health Trading Down 2.0%

Agilon Health stock traded down $0.01 during midday trading on Friday, reaching $0.58. 2,024,525 shares of the stock traded hands, compared to its average volume of 7,721,225. The firm has a market cap of $241.87 million, a PE ratio of -0.61 and a beta of 0.06. The company has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $0.86. Agilon Health has a 12-month low of $0.34 and a 12-month high of $6.08.

Agilon Health (NYSE:AGL) last announced its earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.19). The business had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.46 billion. Agilon Health had a negative return on equity of 100.06% and a negative net margin of 6.60%. Equities research analysts anticipate that Agilon Health will post -0.59 earnings per share for the current year.

Institutional Investors Weigh In On Agilon Health

Hedge funds have recently added to or reduced their stakes in the company. CenterBook Partners LP boosted its stake in shares of Agilon Health by 492.4% in the third quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock valued at $11,771,000 after buying an additional 9,499,012 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Agilon Health by 1,028.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 789,703 shares of the company’s stock valued at $1,816,000 after acquiring an additional 719,751 shares during the period. Geode Capital Management LLC boosted its position in shares of Agilon Health by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 7,156,466 shares of the company’s stock worth $16,462,000 after purchasing an additional 178,477 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Agilon Health by 60.1% during the 2nd quarter. SG Americas Securities LLC now owns 230,912 shares of the company’s stock worth $531,000 after purchasing an additional 86,723 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Agilon Health by 583.2% during the 2nd quarter. XTX Topco Ltd now owns 400,760 shares of the company’s stock worth $922,000 after purchasing an additional 342,100 shares during the period.

Agilon Health News Summary

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Q4 revenue beat estimates — Agilon reported $1.57B in revenue versus the $1.46B consensus, showing top-line resilience for the quarter. MarketBeat/press release
• Positive Sentiment: Company outlined a 2026 target of roughly $5.5B revenue and breakeven adjusted EBITDA, signaling management expects stabilization as it executes its transformation and disciplined contracting strategy. Seeking Alpha article
• Neutral Sentiment: Management made supporting materials available (conference call, slide deck) for investors to assess quarter details and longer-term plan execution; review these for detail on membership, margin levers and timing. Slide deck / conference call
• Negative Sentiment: Earnings miss and profitability concerns — Agilon reported a ($0.46) EPS, missing the ($0.27) consensus by $0.19 and showing a negative net margin and ROE, which fuels short-term downside pressure. MarketBeat earnings summary
• Negative Sentiment: Guidance came in below Street expectations — FY‑2026 revenue guidance ($5.4B–$5.6B) and Q1 revenue guidance missed consensus (~$6.0B and $1.5B expectations respectively), increasing execution risk and prompting investor caution. Press release / guidance
• Negative Sentiment: Analyst downgrade — Barclays cut its price target to $0.50 and set an “underweight” rating, signaling further near-term downside versus recent levels and likely contributing to selling pressure. Benzinga note
• Negative Sentiment: Multiple securities-class-action filings and many law firms are soliciting lead plaintiffs (deadline Mar. 2, 2026), raising litigation risk and potential future legal costs or settlements that can weigh on the stock. Representative notices from firms include Rosen, Schall, Pomerantz, Faruqi and others. GlobeNewswire class action notice

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.